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OBSTETRICS
Exogenous oxytocin modulates human
myometrial microRNAs
Joanna R. Cook, MRCOG; David A. MacIntyre, PhD; Eleni Samara, MSc; Sung Hye Kim, PhD;
Natasha Singh, MRCOG; Mark R. Johnson, MRCOG, PhD; Phillip R. Bennett, FRCOG, PhD;
Vasso Terzidou, MRCOG, PhD
OBJECTIVE: MicroRNAs (miRNAs) play a modulatory role in pathways modeling identified 12 target miRNAs the differential expression
that lead to labor onset, although oxytocin is known to modulate gene
expression within the myometrium. We aimed to identify miRNAs
whose expression is regulated by oxytocin in pregnant human
myometrium.
STUDY DESIGN: Myometrial miRNA expression profiles were
compared between samples collected from women at term before the
onset of labor (no labor; n ¼ 8) and after labor onset after early
exogenous oxytocin treatment (n ¼ 8). Multivariate modelling was
used to assess differences in miRNA profiles. Biologic validation was
undertaken on 3 independent patient cohorts (no labor, n¼ 10; labor
induced with oxytocin, n¼ 8; and spontaneous labor with no oxytocin
treatment, n ¼ 10). In vitro studies that used primary myocytes were
undertaken to assess target miRNA expression after oxytocin treat-
ment. Target genes of candidate miRNAs were identified in silico and
cross-referenced with genes that are known to be associated with
labor or expressed in myometrium.
RESULTS: In total, 1309 miRNAs were analyzed by microarray, of
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2 patient populations in the primary discovery cohorts. Biologic
validation in the independent secondary sample cohorts showed
that oxytocin independently regulated 5 miRNAs (hsa-miR-146b-
3p, hsa-miR-196b-3p, hsa-miR-223-3p, hsa-miR-873-5p, and
hsa-miR-876-5p). Additionally, hsa-miR-146b-3p was increased
both in labor that was induced with oxytocin and in myometrium
from spontaneous labor with no oxytocin treatment compared
with no labor samples. Four of the validated miRNAs (hsa-miR-
146a-5p, hsa-miR-146b-3p, hsa-miR-196b-3p, and hsa-miR-
876-5p) were expressed in primary human myocytes; oxytocin
treatment of these cells replicated the directional changes that
were observed in vivo.
CONCLUSION: Oxytocin alters the expression of a unique set of
myometrial miRNAs. These results suggest a further role for oxytocin
as a signaling molecule that is involved in the regulation of gene
expression during parturition.
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JULY 2015 Ameassociated with serious fetal and
neonatal morbidity and death.2,3 Un-
derstanding the pathways of parturition
is a critical component of developing
effective future therapeutic strategies
that will be designed to predict and
prevent preterm birth and induce labor
more effectively in the case of prolonged
pregnancies.
Tightly regulated changes in gene
expression in myometrium and fetal
membranes are central to the onset of
labor. Increasing evidence implicates
microRNAs (miRNAs), which are small,
noncoding, single-stranded 19-25 nucle-
otide molecules, as regulators of key gene
expression pathways that are involved in
parturition. It is thought that approxi-
mately one-third of the human genome is
regulated by miRNAs,4 primarily at the
posttranscriptional level.5 MiRNAs bindrican Journal of Obstetrics& Gynecology 65.e1
Research Obstetrics ajog.orgto the 3’untranslated region of speciﬁc
target messenger RNAs (mRNAs) to
inhibit their translation to protein via
imperfect complementary base pairing.6
A number of recent studies have exam-
ined miRNA expression during labor
onset in reproductive tissues that have
included the placenta,7 cervix,8 and fetal
membranes.9 Renthal et al10 reported that
the miR-200 family of miRNAs are up-
regulated in laboring murine and hu-
man myometrium at term. In mouse
myometrium, ZEB1 and ZEB2 were
identiﬁed as 2 targets that act as tran-
scriptional repressors of the contraction-
associated genes, which include the
oxytocin receptor and connexin-43,
through a mechanism that involves the
repression of STAT5b, a transcriptional
repressor of the P4 metabolizing enzyme
20a-hydroxysteroid dehydrogenase.11
The oxytocin/oxytocin receptor sys-
tem plays a major role in promoting
myometrial contractility in term and
preterm labor. Although circulating
oxytocin levels do not rise with labor
onset, the term pregnant human uterus
displays increased sensitivity to oxytocin,
mediated via marked up-regulation in
oxytocin receptor mRNA and protein
expression.12 Oxytocin is a potent ute-
rotonin that is used for induction of
labor and in the augmentation of
dysfunctional labor.13 Conversely, oxy-
tocin receptor antagonists are used as
tocolytics in the management of acute
preterm labor.14 In addition to direct
effects on contractions via calcium
signaling, oxytocin has been shown to
function as a signaling molecule that
participates in the inﬂammatory cascade
that is associated with labor that can
induce uterine activation via prosta-
glandin and inﬂammatory cytokine
production.15
Given the known wide range of
oxytocin actions, in this study we have
set out to determine whether oxytocin
may affect the miRNA proﬁle of preg-
nant humanmyometrium at term. To do
this, we initially compared miRNA
expression using microarray analysis in
primary discovery cohorts of myome-
trium in samples taken from women at
term who had not been in labor (NL)
with samples from women whose labor65.e2 American Journal of Obstetrics& Gynecolowas induced or augmented with oxy-
tocin (LOxy). This identiﬁed a series of
candidate miRNAs the expression
of which might be effected by oxytocin.
We then used quantitative real-time
polymerase chain reaction (qRT-PCR)
to examine the expression of these can-
didates in 3 independent, biologic
replication sample cohorts that were
taken from women at term who had not
been in labor, who were in spontaneous
labor but had not had oxytocin treat-
ment, or whose labor had been induced
or augmented with oxytocin. Finally, we
examined the expression of those miR-
NAs that remained candidates after this
secondary biologic validation in isolated
human myocytes in vitro and demon-
strated that their expression was modu-
lated by exogenous oxytocin.
MATERIALS AND METHODS
Study design
To examine miRNA expression patterns,
myometrial biopsy specimens were
obtained initially from women in the
following groups: (1) normal term
pregnancy, delivered by elective cesarean
delivery before labor onset (n ¼ 8
women) and (2) laboring at term after
early exogenous oxytocin treatment,
delivered by emergency caesarean (n¼ 8
women). A second, independent popu-
lation of women was recruited as a bio-
logic validation cohort (NL, 10 women;
LOxy, 8 women; and term spontaneous
labor without any oxytocin [LSpon], 10
women). Samples in the initial cohort
were collected from women at Queen
Charlotte’s and Chelsea Hospital, Lon-
don; the validation samples were taken
from women at Chelsea and West-
minster Hospital, London.
Normal pregnancy was deﬁned by the
absence of medical, surgical, or obstetric
complications. Term was deﬁned as de-
livery at>37 completed weeks gestation.
Labor was deﬁned as regular, painful
contractions with cervical dilation >3
cm. Early exogenous oxytocin treatment
was deﬁned as women who received
intravenous oxytocin when cervical
dilation was <4 cm and when the
duration of treatment was at least for
6 hours.Womenwith premature rupture
of membranes, multiple gestations,gy JULY 2015stillbirth, or fetal anomalies were ex-
cluded. Myometrial biopsy specimens
were taken from the upper margin
of lower segment incisions during ce-
sarean delivery. Samples were washed in
phosphate-buffered saline solution to
remove excess blood, immediately snap
frozen, and stored at e80C. All women
provided written informed consent for
the collection of clinical data and tissue
samples. Ethical approval for the collec-
tion of myometrial biopsy specimens
was granted by the local research ethics
committee (REC 3357).
RNA isolation
Total RNA was extracted from myo-
metrial tissue (30 mg; for the discovery
and validation groups) or cultured cells
(approximately 1  107; for the in vitro
model) using the NucleoSpin column
kit (Macherey-Nagel, Düren, Germany)
according to the manufacturer’s in-
structions. RNA concentration and in-
tegrity were assessed with a nanodrop
spectrophotometer and Bioanalyser 2100
(Agilent Technologies, Santa Clara, CA).
RNA that was isolated from myometrial
tissue was used for miRNA microarray
proﬁling and qRT-PCR validation. RNA
from myometrial cells was used for spe-
ciﬁc miRNA measurement by qRT-PCR.
In vitro modeling: cell culture and cell
treatments
Myometrial tissue was washed in
phosphate-buffered saline solution and
mechanically dissected with 2 sterile
blades; the cells were isolated by incu-
bation with 1 mg/mL of collagenase 1A,
1 mg/mL of collagenase X, and 20 mg of
bovine serum albumin in 40 mL of
Dulbecco’s modiﬁed Eagle’s medium for
45 minutes at 37C. The suspension was
ﬁltered through a cell strainer and
centrifuged at 400g for 5 minutes. The
cells were resuspended and cultured in
Dulbecco’s modiﬁed Eagle’s medium
that contained 10% fetal calf serum, 2
mmol/L L-glutamine, 100 mg/mL peni-
cillin, and 100 mg/mL of streptomycin
and grown in T25 ﬂasks at 5% CO2.
Myocytes were cultured until conﬂuent
and treated with 100 nmol/L oxytocin
(Alliance Pharmaceuticals, Chippenham,
UK) for 1, 2, and 4 hours or 1 mg/mL
TABLE 1
Demographics of original sample cohorts
Characteristic
Term
P valueNot in labor (n[ 8)
In labor receiving
oxytocin (n[ 8)
Median maternal age, y (range) 37 (24e44) 31 (27e36) .08a
Median parity, n (range) 1 (0e2) 0 (0e1) .06a
Black ethnicity, n (%) 1 (11) 1 (13) 1.0b
Median gestational age at delivery,
wk (range)
39 (38e39) 40 (38e41) .06a
The maternal age, parity, ethnicity, and gestation of the original cohort participants are described. There were no significant
differences in age, ethnicity, parity, or race between the 2 clinical groups.
a Continuous variables compared by Mann-Whitney tests; b Discrete variables compared by c2 test.
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vehicle control).
Microarray
Microarray expression analysis of 1309
miRNAs was performed with the miR-
CURY LNAmiRNAmicroarray (version
8.0; Exiqon, Vedbaek, Denmark). Sam-
ples were labeled with miRCURY LNA
miRNA Hi-Power Labeling Kit, Hy3/
Hy5, and were hybridized on the array.
To minimize nonbiologic experimental
variation, samples were randomized
for the array and spike-in oligo nucleo-
tide controls were included. The quan-
tiﬁed signals (background corrected) were
normalized with the global locally we-
ighted scatterplot smoothing regression
algorithm.16 The positive effect of no-
rmalization was conﬁrmed by assessment
of log ratio/log mean-intensity plots.
Real-time qRT-PCR for miRNA
QRT-PCR was used to quantify the
expression of candidate miRNAs with
the miRCURY LNA kit (Exiqon) with
0.05 ng complementary DNA. LNA as-
says were custom designed (Exiqon) for
miRNAs of interest: hsa-miR-21-5p
(204230), hsa-miR-29a-3p (204698),
hsa-miR-29a-5p (204430), hsa-miR-
29b-3p (204679), hsa-miR-29c-3p
(204729), hsa-miR-29c-5p (204132),
hsa-miR-141-3p (204504), hsa-miR-
146a-5p (204688), hsa-miR-146b-3p
(204374), hsa-miR-196b-3p (204619),
hsa-miR-223-3p (204256), hsa-miR-
873-5p (204175), and hsa-miR-876-5p
(204527). MiRNA expression data were
normalized to 5S ribosomal RNA
(203906).17
Statistical analysis
Background signal was deﬁned as
expression 1.2 times the 25th percentile
of overall signal intensity and subtracted
from the array dataset. MiRNAs that
were detected above background in 6
samples in any phenotypic group, and
therefore expressed in most of those
samples, were included in the analysis.
Array data were subjected to unsuper-
vised principal components analysis
(PCA) and supervised partial least
squaresediscriminatory analysis (PLS-
DA) with the use of SIMCA-P (Softindependent modelling of class analogies-
P; version 13.0.2; Umetrics, Umeå, Swe-
den). Data were scaled to unit variance by
the division of each variable by 1/(Sk),
where Sk represents the standard deviation
value of the variable to ensure that all
variables retained equal importance dur-
ing the generation of the model.
Goodness-of-ﬁt and predictive ability pa-
rameters were calculated (the latter by a 7-
round internal cross-validation of the
goodness-of-ﬁt parameter) and used to
assess model ﬁt.18,19 Although PCA per-
mits an overall examination of covariance
in the datasets, PLS-DA was used to
examine speciﬁc differences in themiRNA
proﬁles that were associated with patient
groups. PLS-DA analysis differs from PCA
in that the algorithm is provided with class
membership of clinical sample groups
and components are projected and
rotated around the axis to obtain
maximum separation between these
classes, thus permitting the best
description of class-related variability.
MiRNAs that differed most between
classes were identiﬁed by examination
of their calculated variable importance
for the projection (VIP) score, which
was calculated in SIMCA-P with a
proprietary algorithm. The VIP score
describes the relative contribution of
each miRNA (X variables) to patient
class variation (Y variables) accounted
for by each component in the PLS-DA
model. A VIP score >1 is considered
to indicate an important contributor to
the separation of patient classes that are
observed in the PLS-DAmodel.18 In thisJULY 2015 Amestudy, miRNAs that exhibit VIP scores
>1.5 were deﬁned as signiﬁcant and
selected for further investigation.
For qRT-PCR, relative expression of
individual miRNAs in tissue and cell
samples was calculated by the DDCT
method. Statistical signiﬁcance of the
data was inferred with a 2-tailed Mann-
Whitney test for tissue samples and a
1-way analysis of variance for treated
cells. A probability value of < .05 was
considered statistically signiﬁcant.
Identification of potential target
genes
Target genes of the candidate differen-
tially expressed myometrial miRNAs
were sought with the use of the miR-
TarBase platform, which describes
experimentally validated miRNA targets
in the current literature (http://
mirtarbase.mbc.nctu.edu.tw).20 These
candidate genes were cross-referenced
with genes that previously were re-
ported in gene microarray studies of
pregnant human myometrium21,22 and
those known to be implicated in partu-
rition. This method produced a focused
short-list of validated potential gene
targets.
RESULTS
Exogenous oxytocin modulates the
expression of a subset of miRNAs in
human myometrium
Analysis of patient demographic charac-
teristics revealed no signiﬁcant differences
in age, ethnicity, parity, or gestation be-
tween those women who providedrican Journal of Obstetrics& Gynecology 65.e3
FIGURE 1
Multivariate modeling of microRNA expression inmyometrium of women laboringwith oxytocin and thosewomen
not in labor
A, Unsupervised principal components analysis of myometrial microRNA expression did not reveal any clear clustering of patients not in labor (blue) or
patients laboring with oxytocin (red ), which indicates that most variance in the data was independent of oxytocin treatment. B, Supervised partial least
squaresediscriminatory analysis of microRNA expression profiles facilitated separation of the patient classes. C, Variable importance plot scores show
which individual microRNA variance contributes to the separation of phenotype (ie, VIP, 1.5).
LOxy, labor with oxytocin; NL, not in labor; PC1, first principal component; PC2, second principal component; VIP, variable importance plot.
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taken before labor onset (n ¼ 8) and
those who received exogenous oxytocin
(n ¼ 8; Table 1). A total of 494 miRNAs
were detected above background
expression levels and were used for
multivariate modeling of LOxy and NL
myometrium proﬁles (Figure 1).65.e4 American Journal of Obstetrics& GynecoloUnsupervised PCA was ﬁrst used to
assess overall variation of the dataset. As
seen in Figure 1, A, no obvious clus-
tering of the 2 patient populations
was detected, which indicates that
most miRNA variation in the sample
population was independent of oxytocin-
induced/augmented labor. To focus ongy JULY 2015oxytocin-speciﬁceinduced variation in
the miRNA proﬁles, supervised PLS-DA
was used (Figure 1, B). Analysis of the
calculated VIP values (Figure 1, C)
permitted selection of a panel of 12 miR-
NAs that were most responsible for the
observed separation of the 2 patient pop-
ulations. Those miRNAs with a VIP score
TABLE 2
Demographic data from the biologic validation cohorts
Characteristics
Term
P value
Term, in labor, receiving
oxytocin (n[ 9) P value
Not in labor
(n[ 10)
In labor, no exogenous
oxytocin (n[ 8)
Median maternal age, y (range) 33 (19e41) 30 (19e37) .7a 36 (26e41) .1a
Median parity, n (range) 1 (0e2) 0.5 (0e2) .56a 0 .01a
Black ethnicity, n (%) 1 (10) 0 1.0b 1 (10) 1.0b
Median gestational age at delivery, wk (range) 39 (37e41) 39 (37e41) .32a 40 (38e42) .08a
The maternal age, parity, ethnicity, and gestation of the validation cohort participants are described. There were no significant differences in age, ethnicity, or gestation between the nonlaboring and
laboring with exogenous oxytocin groups, however, women in the laboring with exogenous oxytocin groups were more likely to be primiparous (P¼ .01). There were no significant differences in age,
parity, ethnicity, or gestation between the nonlaboring and spontaneous laboring groups.
a Continuous variables compared by Mann-Whitney tests; b Discrete variables compared by c2 test.
Cook. Oxytocin modulates human myometrial miRNAs. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Research1.5 were deﬁned as signiﬁcantly con-
tributing to the separation in the model.
These comprised hsa-miR-21-5p, hsa-
miR-29a-3p, hsa-miR-29b-3p, hsa-miR-
29c-3p, hsa-miR-29c-5p, hsa-miR-141-3p,
hsa-miR-146a-5p, hsa-miR-146b-3p, hsa-
miR-196b-3p, hsa-miR-223-3p, hsa-miR-
873-5p, and hsa-miR-876-5p.
The laboring myometrial miRNA
profile of women who were treated
with oxytocin differs from those in
spontaneous labor
To validate our ﬁndings, qRT-PCR was
used to examine the expression of the
12 selected target miRNAs in myo-
metrial samples that were isolated fromTABLE 3
Expression of microRNAs in original
reaction
MicroRNA
Women
compare
Unadjus
hsa-miR-200c-3p .25
hsa-miR-29c-3p .023
hsa-miR-29b-3p .022
hsa-miR-223-3p .012
hsa-miR-873-5p .0007
hsa-miR-876-5p .0009
Univariate logistic regression modeling was used to compare expr
were measured with real-time polymerase chain reaction in the s
taken from women in labor who received oxytocin and women n
Multivariate logistic regression was also used to adjust for parity,
slightly dissimilar (P¼ .06). The probability values remained cons
introduce bias to our results. Analysis was carried out using ST
Cook. Oxytocin modulates human myometrial miRNAs. Amsecondary, independent validation co-
horts of women at term not in labor
(n ¼ 10), at term in labor after early
oxytocin treatment (n ¼ 8) and addi-
tionally women in spontaneous labor
not receiving oxytocin (n ¼ 10). De-
mographic characteristics of the vali-
dation cohort are provided in Table 2.
No signiﬁcant differences in age,
ethnicity, or gestation between
the patient groups were observed,
although all women who received
oxytocin were nulliparous, which is
consistent with the common clinical
use of exogenous oxytocin. To examine
whether parity impacts on the ex-
pression of our target miRNAs, wecohort using polymerase chain
in labor who received exogenous oxytocin
d with women not in labor, P value
ted Adjusted for parity
.15
.012
.034
.0038
.0040
.0042
ession of a selection of individual myometrial microRNAs that
ame samples as those analyzed by microarray. Samples were
ot in labor. The findings reproduce those of the microarray.
which although not significantly different in the 2 groups, was
istent, and we conclude that small variations in parity did not
ATA software (StataCorp LP, College Station, TX).
J Obstet Gynecol 2015.
JULY 2015 Ameundertook logistic regression on avai-
lable PCR data from 6 miRNAs that
were analyzed in our discovery set.
When adjusted for parity, relative ex-
pression of miRNAs was not affected
(Table 3). Similar analyses were not
performed in the validation cohort
because all women in the LOxy group
were primiparous and most women
in the NL group were multiparous.
Differential expression of 6 of the
12 candidate miRNAs (hsa-miR-146a-
5p, hsa-miR-146b-3p, hsa-miR-196b-
3p, hsa-miR-873-5p, hsa-miR-876-5p,
and hsa-miR-223-3p) was conﬁrmed in
the myometrium of women who
received oxytocin in labor (LOxy vs NL;
Figure 2). Expression of hsa-146a-5p,
hsa-miR-196b-3p, hsa-miR-873-5p,
and hsa-miR-876-5p was decreased
in LOxy myometrium (e4 fold change,
P ¼ .02; e3.3 fold change, P ¼ .04; e5
fold change, P ¼ .01, and e10 fold
change, P ¼ .02, respectively), whereas
hsa-miR-146b-3p and hsa-miR-223-3p
levels were increased in the myome-
trium of oxytocin-treated women (2.7
fold change, P ¼ .0055; 9 fold change,
P ¼ .0025, respectively). Only hsa-miR-
146b-3p was found to be up-regulated
in both LSpon (3.3 fold change, P ¼
.04) and LOxy groups (Figure 2).Oxytocin treatment regulates miRNA
expression in human myocytes
To investigate whether the observed
miRNA differences represent a signature
of dysfunctional labor that requirerican Journal of Obstetrics& Gynecology 65.e5
FIGURE 2
Biologic validation with polymerase chain reaction in a second cohort
Expression of A-F, 6 microRNAs (hsa-miR-146a-5p, hsa-miR-146b-3p, hsa-miR-196b-3p, hsa-miR-223-3p, hsa-miR-873-5p and hsa-miR-876-5p)
remained significantly different in nonlaboring women compared with those women laboring with oxytocin. However, when expression levels of
microRNAs were compared between the nonlaboring group and those laboring spontaneously without oxytocin, only hsa-miR-146b-3p was expressed
differentially. G-L, Hsa-miR-21-5p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-29c-5p, and hsa-miR-141-3p did not alter in
myometrium from women who received oxytocin or in those laboring spontaneously in our validation population. The single asterisk indicates P< .05;
the double asterisks indicate P < .01.
LOxy, women laboring with oxytocin; LSpon, laboring spontaneously without oxytocin; NL, nonlaboring women; NS, not significant.
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Research Obstetrics ajog.orgaugmentation with oxytocin or whether
they represent a direct effect of oxytocin
on myometrial miRNA expression, we
used an in vitro model of primary
cultured myocytes. Human myocytes
that were taken from women before the
onset of labor (n ¼ 5) were treated with
oxytocin, and levels of the 6 miRNAs
found to be differentially expressed
in vivo after oxytocin treatment were
examined. Treatment of these cells with
oxytocin resulted in signiﬁcant down-
regulation of hsa-miR-146a-5p, hsa-
miR-196b-3p, and hsa-miR-876-5p
(n ¼ 5; 1-way analysis of variance; p ¼
.008, .02, and .02, respectively), consis-
tent with in vivo observations
(Figure 3). Conversely, hsa-miR-223-3p
and has-miR-873-5p were not expressed65.e6 American Journal of Obstetrics& Gynecoloat detectable levels in cultured myo-
cytes, and the expression of hsa-miR-
146b-3p was not effected by oxytocin
treatment. Our ﬁndings provide good
evidence that oxytocin regulates hsa-
miR-146a-5p, hsa-miR-196b-3p, and
hsa-miR-876-5p, whereas hsa-miR-
146b-3p is not induced by oxytocin
but increases in response to the process
of labor itself.
Potential targets of oxytocin-
regulated miRNAs
Potential target genes of oxytocin-
regulated miRNAs were sought with
the use of the miRTarBase platform
and were cross-referenced with genes
that are known to be expressed in
pregnant human myometrium orgy JULY 2015implicated in parturition (Table 4). Hsa-
miR-146a-5p, hsa-miR-146b-3p, and
hsa-miR-223-3p have been linked with
functional studies to potential target
genes within the myometrium, whereas
hsa-miR-196b-3p, hsa-miR-873-5p, and
hsa-miR-876-5p, so far, have not been
associated with the regulation of genes
within the myometrium.
COMMENT
At the end of pregnancy, oxytocin acts as
a potent stimulator of uterine contrac-
tions and accordingly is used extensively
for induction of labor, whereas oxytocin
receptor antagonists are used widely to
delay preterm birth. However, the
effectiveness of these treatment strategies
is variable at best. Understanding how
FIGURE 3
Myocyte expression of hsa-miR-146a-5p, hsa-miR-146b-3p, hsa-miR-
196b-3p, and hsa-miR-876-5p after oxytocin exposure
A, Hsa-miR-146a-5p expression in myocytes was reduced significantly after exposure to oxytocin
(100 nmol/L) for 2 hours with no change in expression seen at 1 and 4 hours. B, Hsa-miR-146b-3p
expression in myocytes was not altered by the addition of oxytocin. C, Hsa-miR-196b-3p expression
in myocytes was reduced significantly after exposure to oxytocin for 2 hours with no change in
expression seen at 1 and 4 hours. D, Hsa-miR-876-5p expression in myocytes was reduced
significantly after exposure to oxytocin for 1, 2, and 4 hours. Values are expressed as mean SEM
(n ¼ 4). The double asterisk indicates a probability value of < .01; the single asterisk indicates a
probability value of < .05.
NS, non-stimulated; OXT, oxytocin.
Cook. Oxytocin modulates human myometrial miRNAs. Am J Obstet Gynecol 2015.
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rition is critical for enabling the devel-
opment of more effective therapeutic
strategies to predict and prevent preterm
birth or, alternatively, for induction of
labor in prolonged pregnancies. This
study reports that oxytocin affects the
miRNA proﬁle of human myometrium
at term. We describe a miRNA “ﬁnger-
print” that is expressed differentially in
myometrium after oxytocin administra-
tion that is distinct from the miRNA
proﬁle that was observed in the samples
that were obtained during spontaneous
labor. Our results highlight a role for
oxytocin in the regulation of speciﬁc
myometrial miRNAs both in vivo and
in vitro.
Our qRT-PCR analysis of selected
myometrial miRNAs in samples thatwere derived from women in sponta-
neous labor or after oxytocin adminis-
tration indicates that oxytocin drives the
labor phenotype through a distinct
mechanism to that observed in sponta-
neous labor. This observation is consis-
tent with previous proteomic studies of
myometrial biopsy specimens that were
obtained from women in spontaneous
and oxytocin-induced labor.23 However,
it is feasible that changes in the myo-
metrial miRNA proﬁle after exogenous
oxytocin simply may reﬂect underlying
molecular differences in women who
experience dysfunctional labor and who
subsequently require clinical interven-
tion and induction with oxytocin. To
examine whether observed differences in
miRNA expression represent a signature
of dysfunctional labor or reﬂect a directJULY 2015 Ameeffect of oxytocin on the myometrium,
we used an established in vitro model of
cultured primary myocytes.24,25 Treat-
ment of these cells with oxytocin led to
the transient suppression of hsa-miR-
146a-5p, hsa-miR-196b-3p, and hsa-
miR-876-5p that were consistent with
in vivo observations. In contrast, hsa-
miR-146b-3p expression was not
altered in myocytes that were treated
with oxytocin, although its levels were
increased in both spontaneous and
oxytocin-treated laboring myometrium
samples. This ﬁnding highlights hsa-
miR-146a-5p, hsa-miR-196b-3p, and
hsa-miR-876-5p as oxytocin responsive
miRNAs, whereas hsa-miR-146b-3p
likely represents a miRNA that is mo-
dulated as a consequence of the inﬂam-
matory process of labor, which itself is
stimulated up-stream by oxytocin.
Although further work is required to
deﬁne the biologic signiﬁcance of these
changes, interrogation of the miRTar-
Base platform enabled the identiﬁcation
of putative gene targets of thesemiRNAs.
Of particular interest, hsa-miR-146a-5p,
which was reduced in myometrial sam-
ples from oxytocin-treated women and
also in myometrial cells treated with
oxytocin, is a known suppressor of nu-
clear factor kappa B (NF-kB) activity in
human breast,26 pancreatic,27 and
gastric28 cancer cells, which results in the
suppression of NF-kB target genes that
include the key labor-associated genes
interleukin-8, interleukin-6, and matrix
metalloproteinase-9. Decreased levels
of hsa-miR-146a-5p that were observed
in oxytocin-treated myometrial tissue
and cells may reﬂect withdrawal of
NF-kB inhibitory activity and promote
a contractile phenotype. Consistent with
this, hsa-miR-146a-5p has also been
shown to attenuate the expression of a-
smooth muscle actin, which is the major
protein constituent of uterine smooth
muscle and essential component of the
contractile machinery, in human dermal
ﬁbroblasts.29 We recently have shown a
proinﬂammatory role for oxytocin in
human gestational tissues whereby
speciﬁc stimulation of oxytocin by its
ligand drives the sequential activation of
MAPKinases and NF-kB and subsequent
prostaglandin and proinﬂammatoryrican Journal of Obstetrics& Gynecology 65.e7
TABLE 4
Potential gene targets of oxytocin regulated microRNAs
MicroRNA
Direction of expression
change with oxytocin
Experimentally validated gene targets
that are known to be expressed in
myometriuma or implicated in parturitionb
hsa-miR-146a-5p Decrease Toll-like receptor 2b31
Interleukin 8a26,27,36
Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1b26,27,37
Toll-like receptor 4b38
BCL2-related protein A1a39
hsa-miR-146b-3p Increase Platelet-derived growth factor beta
polypeptideb24
hsa-miR-223-3p Increase Leukemia inhibitory factora40
hsa-miR-196b-3p Decrease No matches
hsa-miR-876-5p Decrease No validated targetsc
hsa-miR-873-5p Decrease No validated targetsc
Potential target genes of oxytocin-regulated microRNAs were sought with the use of the miRTarBase platform and cross-
referenced with genes that are known to be expressed in pregnant human myometrium or implicated in parturition.21,22
a Experimentally validated gene targets of microRNAs were cross-referenced with genes that are known to be expressed in
pregnant human myometrium; b Reported target known to be involved in parturition; c As per miRTarBase, August 2014.
Cook. Oxytocin modulates human myometrial miRNAs. Am J Obstet Gynecol 2015.
Research Obstetrics ajog.orgcytokine and chemokine production.30
This suggests an additional and hith-
erto unrecognized role for oxytocin
in the onset of human labor via modu-
lation of the inﬂammatory pathways that
lead to NF-kB activation. Our ﬁnding
that oxytocin can reduce hsa-miR-146a-
5p expression may provide a further
mechanistic link between miRNA
expression and NF-kB activation. Further,
hsa-miR-146a-5p has also been shown to
interfere with TLR2 downstream signaling
and cytokine production,31 which suggests
that oxytocin-induced suppression of
hsa-miR-146a-5p could result in enhanced
TLR2-dependent NF-kB signaling that is
analogous to the activation of this pathway
by lipopolysaccharide because occurs in
infection-induced preterm labor.
Currently, miRTarBase does not reveal
putative experimentally validated gene
targets for hsa-miR-876-5p and hsa-
miR-873-5p. However, hsa-miR-146b-
3p, which was increased signiﬁcantly in
myometrial samples from both sponta-
neous and oxytocin-induced labors, is
linked functionally to the regulation of
platelet-derived growth factor beta
polypeptide, which is an inﬂammatory
cytokine that recently has been reported
as being released by uterine myocytes in
response to stretch.24 Hsa-miR-146b-3p
has also been implicated recently in
regulating mRNA levels of TRAF6 and
IRAKI, which are proteins involved in
the modulation of NF-kB activation.32
In this context, hsa-miR-146b-3p is
thought to function in a negative feed-
back loop, whereby its induction by both
interleukin-6 and signal transducer
and activator of transcription 3 result
in the inhibition of both NF-kB-depen-
dent IL6 expression and downstream
activation of signal transducer and acti-
vator of transcription 3.33 Interleukin-6
is a key inﬂammatory mediator in pa-
rturition and stimulates cervical and
fetal membrane remodeling. Thus,
increased expression of hsa-miR-146b-
3p in response to labor may represent a
homeostatic response to the raised in-
ﬂammatory mediators accompanying
labor, such as interleukin-6.
Both hsa-miR-223-3p and hsa-miR-
873-5p were found to be expressed
differentially in laboring myometrium65.e8 American Journal of Obstetrics& Gynecolothat was obtained from women who
received exogenous oxytocin; however,
we were unable to detect their expression
in primary human myocyte cultures. We
hypothesize that their presence in myo-
metrial tissue may be the result of the
inﬂammatory cell inﬁltrate that remains
present inwhole tissue extracts but would
not persist in cell culture. Regardless of
their cell of origin, miRNAs may act in a
paracrine fashion by exerting an effect on
adjacent and distant cell types.34 This
represents an additional challenge to
establish mechanistic links between such
miRNAs and their functional gene tar-
gets. Recent studies have also identiﬁed a
labor-associated increase of hsa-miR-
223-3p in human cervical tissue8 and in
chorioamniotic membranes in the pres-
ence of inﬂammation.9 Hsa-miR-223-3p
has been found to target IKKa during
monocyte-macrophage differentiation,
which suggests a possible role in the
noncanonical and canonical NF-kB
pathways,35 which are important in both
term and preterm labor.
It has been reported that labor is
associated with increased myometrial
expression of members of the miR-200gy JULY 2015family (miR-200a/141 and miR-200b/c/
429).10,11 In our microarray, hsa-miR-
200a/b/c and hsa-miR-429 were not
expressed above background; although
hsa-miR-141 was detected, it was not
expressed differentially in those women
who received oxytocin. This potentially
supports the hypothesis that women
who require oxytocin during labor
exhibit a dysfunctional miRNA expres-
sion proﬁle; however, we acknowledge
that the authors of these studies do not
explicitly state that their study partici-
pants had not received oxytocin.
In conclusion, our ﬁndings provide a
novel insight into how oxytocin con-
tributes to normal human parturition
and modulates human myometrial
miRNAs. Although further research is
required to understand the role of
these miRNAs in myometrial contrac-
tility and function, our results implicate
oxytocin as a signaling molecule in their
regulation. -
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